

Sl. No.	Company Name
69.	PPD Pharmaceutical
70.	PRA International
71.	Quintiles
72.	Ranbaxy Laboratories Ltd.
73.	Reliance
74.	Roche
75.	Sandoz Private Ltd., Mumbai
76.	Sanofi-Aventis
77.	Serdia Pharmaceuticals
78.	Siro Clinpharm Pvt. Ltd.
79.	Spectrum Clinical Reserch
80.	Sristek, Hyderabad-500019
81.	St. John's National Academy of Heath Sciences, Bangalore
82.	Sun Pharma
83.	Takeda
84.	The George Institute India, Hyderabad
85.	The Global Institute for Global Health, Hyderabad
86.	Theorem Clinical Research
87.	Torrent Pharmaceutical Ltd.
88.	Trident Clinical Research India Pvt .Ltd., Thane(W)
89.	UCB
90.	United Therapeutics Corporation
91.	Veeda Clinical Research Pvt. Ltd.
92.	Virchow Biotech Pvt. Ltd., Hyderabad
93.	Wyeth Pharmaceuticals Pvt. Ltd.

Acute shortage of Oncologists

281. DR. PRABHAKAR KORE: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that the country is facing an acute shortage of oncologists, surgical oncologists and radio-therapists, which affects the expansion plans of cancer hospitals in the country;

- (b) if so, the present ratio of oncologists to cancer patients in the country; and
- (c) the steps being taken by Government to overcome the shortage of oncologists in the country and the details thereof?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI JAGAT PRAKASH NADDA): (a) to (c) There is no central data available to ascertain the quantum of shortage of cancer specialists in the country. However, to increase the number of seats in Super speciality courses in Medical Oncology, Surgical Oncology and broad speciality course in Radiotherapy, the ratio of number of Post-Graduate (PG) teachers to the number of students to be admitted has been now increased to 1:3 for a Professor subject to a maximum of 6 PG seats per unit per academic year. Oncology in its various aspects has focus in case of new AIIMS and many upgraded institutions under Pradhan Mantri Swasthya Suraksha Yojna (PMSSY). The National Cancer Institute at Jhajjar and 2nd campus of Chittranjan National Cancer Institute, Kolkata also have a mandate for capacity building. The mandate of State Cancer Institutes (SCI) and Tertiary Care Cancer Centres (TCCC) supported under National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Disease and Stroke (NPCDCS) includes enhancing of trained manpower for cancer.

Rolling back of drug price control order

282. SHRI K.N. BALAGOPAL: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

- (a) whether the Ministry have noticed about the decision to roll back the drug price control in India;
- (b) if so, whether the Ministry is aware about the probable effect on health sector due to the lifting of drug price control, if so, the details thereof;
- (c) whether the Ministry was consulted before taking the decision to roll back drug price control; and
- (d) if so, the details thereof?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI JAGAT PRAKASH NADDA): (a) Prices of drugs are fixed by National Pharmaceutical Pricing Authority (NPPA) under the Department of Pharmaceuticals. That Department has informed that since notification of Drugs Price Control Order (DPCO), 2013, no prices have been rolled back except in case of two drugs which were inadvertently fixed by NPPA.

- (b) to (d) Do not arise.